Arpeggio Bio

Summer 2019Active

Arpeggio Bio develops drugs targeting transcription factors using AI…

Save

Arpeggio Bio

Summer 2019Active

Arpeggio Bio develops drugs targeting transcription factors using AI…

Save

Company details

Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.

Location

Boulder, CO, USA

Founded

Unknown

Request the Arpeggio Bio report.

Arpeggio Bio has no report yet. Sign in with your email to request one.